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DOI 10.1016/j.ccr.2011.11.003SUMMARYTumor immune surveillance and cancer immunotherapies are thought to depend on the intratumoral infiltra-
tion of activated CD8+ T cells. Intratumoral CD8+ T cells are rare and lack activity. IL-10 is thought to
contribute to the underlying immune suppressive microenvironment. Defying those expectations we
demonstrate that IL-10 induces several essential mechanisms for effective antitumor immune surveillance:
infiltration and activation of intratumoral tumor-specific cytotoxic CD8+ T cells, expression of the Th1 cyto-
kine interferon-g (IFNg) and granzymes in CD8+ T cells, and intratumoral antigen presentation molecules.
Consequently, tumor immune surveillance is weakened in mice deficient for IL-10 whereas transgenic over-
expression of IL-10 protects mice from carcinogenesis. Treatment with pegylated IL-10 restores tumor-
specific intratumoral CD8+ T cell function and controls tumor growth.INTRODUCTION
Human tumor cells display a number of mutations and tran-
scriptional alterations (Wood et al., 2007), distinguishing their
transcribed genome from the patient’s immunological antigen
profile described as immunological self (Segal et al., 2008).
Research into the immune system’s recognition of tumors over
the last 25 years has established that human tumors are immu-
nologically recognized by cytotoxic T cells (Knuth et al., 1984;
Lee et al., 1999). CD8+ cytotoxic T cells have been shown to
recognize point mutations in oncogenes, onco-fetal proteins
and cell type-specific genes (Ja¨ger et al., 2003; Van Der Brug-Significance
Cancer vaccines and adoptive T cell transfers stimulate an imm
tumor-specific cytotoxic T cells. However, the immune suppre
and inhibits T cell infiltration into tumors, limiting effectivenes
ously thought to contribute to the immune suppressive milieu,
ical control of tumors. IL-10 induces CD8+ T cell infiltration an
induction of IFNg in CD8+ T cells, IL-10 induces expression o
the cellular and molecular mechanisms to elicit immunologica
of late stage cancers.
Cangen et al., 2002). However, spontaneous immune-mediated
remissions are rare. Immune therapies such as tumor vaccines
or adoptive T cell transfers frequently aim to increase the num-
ber of tumor-specific T cells. However, tumors in patients can
progress despite the presence of dramatic vaccine-induced
expansion of tumor antigen-specific T cells and the continued
expression of the immunogenic antigens in the tumor (Rosen-
berg et al., 2005). Moreover, the presence of endogenous or
vaccine-induced tumor-reactive T cells in systemic circulation
does not necessarily improve clinical outcomes (Lee et al.,
1999; Rosenberg et al., 2005). In contrast, the presence and
activity of CD8+ effector T cells in the tumor tissue confers anune response against tumors by increasing the prevalence of
ssive microenvironment of tumors attenuates T cell function
s of cancer immunotherapy. We describe how IL-10, previ-
overcomes immunological obstacles to restore immunolog-
d their cytotoxic activity within pre-established tumors. By
f intratumoral antigen presenting molecules. This uncovers
l control of tumors, and delineates a strategy for treatment
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et al., 1998).
Correspondingly, immune evasion of human and mouse
tumors can be mediated by mechanisms that reduce tumor
cell-specific activity of CD8+ T cells. These include loss of
antigen expression, reduced tumoral expression of IFNg recep-
tors, expression of immune suppressive surface molecules or
low expression of major histocompatibility complex molecules
(MHC-I/II) (Seliger et al., 2002), limiting the presentation of tumor
antigens, and recognition by tumor-infiltrating T cells. Expres-
sion of MHC molecules on human tumor cells can be restored
in vitro by IFNg treatment (Seliger et al., 2002) and correspond
with adoptive T cell transfer in responding patients (Dudley
et al., 2002).
Seemingly in contrast to the observations described above is
the century-old observation that tissue inflammation correlates
with an increased local incidence of tumors, a higher progression
rate and the decreased survival of cancer patients (Balkwill et al.,
2005; Balkwill and Coussens, 2004). Indeed, the microenviron-
ment of human tumors appears to be polarized toward an
immune response resembling inflammatory diseases and is
characterized by the expression of similar inflammatory cyto-
kines (Langowski et al., 2007; McKenzie et al., 2006). These find-
ings lead us to hypothesize that it is not immune recognition
per se, but rather the polarization and the effector function of
the immune response that might be deregulated by tumors
(Mumm and Oft, 2008). Redirection of this immune pathology
into cytotoxic effectors is a current topic of significant interest
and could present a powerful tool in the arsenal against late
stage cancer.
Interleukin 10 (IL-10) can be expressed by most T cells
including regulatory T cells (Tregs), antigen presenting cells,
macrophages as well as epithelial cells (Moore et al., 2001).
IL-10 inhibits secretion of the proinflammatory cytokines IFNg,
tumor necrosis factor a (TNFa), IL-1b, and IL-6 by CD4+ T cells
and the expression of several cytokines including IL-12 by
antigen presenting cells in vitro. IL-10 also inhibits the expres-
sion of MHC molecules and costimulatory molecules at several
levels (Moore et al., 2001). It has also been demonstrated that
IL-10 can impair secondary CD8+ T cell responses (Kang and
Allen, 2005), whereas viral and tumor clearance can be
enhanced in the absence of IL-10 (Brooks et al., 2006; Vicari
et al., 2002). In addition, it has been suggested that IL-10 con-
tributes to an immune suppressive tumor microenvironment,
because tumor cell lines cultured in vitro can express IL-10.
Thus, most attention has been devoted to studying the negative,
regulatory function of IL-10 in inflammatory diseases or bacterial
and parasitic infections where IL-10 expressed by Th1 cells
suppresses TNFa- or IL-12-mediated inflammation and attenu-
ates immune-mediated clearance of infections (O’Garra and
Vieira, 2007; Trinchieri, 2007).
Clinical studies using recombinant IL-10 to treat patients with
inflammatory diseases achieved moderate therapeutic effects
(O’Garra et al., 2008). Peripheral blood cells of colitis patients
treated with IL-10 showed reduced secretion of TNFa and
IL-1b (Tilg et al., 2002). In humans, treated lipopolysaccharide
(LPS) and IL-10 reduced TNFa but, contrary to prevailing dogma,
elevated IFNg and Granzyme B in the serum (Lauw et al., 2000;
Pajkrt et al., 1997) IL-10 can also stimulate effector cells of the782 Cancer Cell 20, 781–796, December 13, 2011 ª2011 Elsevier Inchumoral and cytotoxic arm of the immune system (Chen and
Zlotnik, 1991; Groux et al., 1998). Overexpression of IL-10 in
tumor cells transplanted in mice led to tumor rejections impli-
cating CD8+ T cells, NK cells or the antiinflammatory properties
of IL-10 (Moore et al., 2001; Zheng et al., 1996). Therapeutic
administration of recombinant human IL-10-induced antitumor
immunity against fibrosarcomas in mice (Berman et al., 1996;
Fujii et al., 2001). The explanation of how IL-10 reduces tumor
growth despite its immune inhibitory functions on antigen pre-
sentation, cytokine expression, and T helper cells remains
enigmatic.
When screening a large number of immune modulating cyto-
kines for an influence on the growth of tumors in immune compe-
tent mice, we confirmed the strong antitumor activity of IL-10.
We therefore set out to analyze the role and mechanism of
IL-10 in tumor immune surveillance and rejection of large tumor
masses.RESULTS
IL-10 Deficiency Increases Tumor Incidence
and Decreases Immune Surveillance
We subjected wild-type (WT) or IL-10 deficient (IL-10/)
C57BL/6 mice to a two-step skin carcinogenesis protocol (Lan-
gowski et al., 2006). WT mice developed many tumors and inva-
sive carcinomas within 1 year after tumor initiation. Despite their
tumor burden, most WT mice have a normal life span. IL-10/
mice developed increased numbers of tumors and all suc-
cumbed to tumors within 1 year after the initiating carcinogen
treatment (Figures 1A and 1B). BALB/cmice are less susceptible
to chronic inflammation than C57BL/6 mice, but IL-10 deficiency
similarly increased the susceptibility of BALB/c mice for skin
tumors (Figure 1C).
Due to the central role of IL-10 in controlling inflammation
and the established role of inflammation in the promotion of
two-step skin carcinogenesis, we analyzed the infiltration of
inflammatory cells and the expression of inflammatory mole-
cules in the skins of carcinogen treated WT mice, IL-10/
mice, or IL-10TG mice that overexpress human IL-10 in all
antigen presenting cells under the control of the MHCII promoter
(Groux et al., 1999). Remarkably, IL-10TGmice were resistant to
tumor induction (Figure 1D) but, surprisingly, given the putative
role of IL-10 in inhibiting inflammation, showed a level of infiltra-
tion with inflammatory macrophages (CD11b+) equivalent to the
two other genotypes (Figure 1E). In search of a molecular mech-
anism for the tumor susceptibility we found that MHC-I mole-
cules were expressed significantly lower in skin lesions from
WT or IL-10/ mice (Figures 1F–1H). Additionally, the mRNA
of Granzyme A and Granzyme B, molecules mediating cytotoxic
effector and tumor immune surveillance functions, were signifi-
cantly reduced in IL-10/ versusWT skins (Figure 1I). We further
found that, surprisingly, IL-10TG mice showed increased
numbers of skin infiltrating CD8b+ T cells and higher expression
of the Th1 associated cytokine IFNg accompanied with in-
creased expression of MHC molecules compared to IL-10/
mice (Figures 1F and 1J–1L). These data indicated that in the
context of transformed tissue, IL-10 not only fails to downregu-
late CD8+ T cell responses, IFNg, and expression of antigen.
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Figure 1. IL-10 Controls Tumor Immune Surveillance against Skin Tumors
(A and B) Tumor incidence 5 months after initiation (A) and mortality (B) after chemical carcinogenesis in IL10/ and WT C57BL/6 mice.
(C) Tumor incidence 5months after chemical carcinogenesis in IL10/ andWTBALB/cmice. Data are representative of 8–12mice per group, performed twice in
C57BL/6 and three times in BALB/c.
(D) Tumor development after chemical carcinogenesis protocol in IL-10 TG, WT and IL-10/ mice.
(E) Macrophage infiltration into skins in IL-10 TG, WT, and IL-10/Balb/c mice (quantified CD11b IHC intensity; light absorption units).
(F–H). Quantitation of MHC-I protein expression in hyperplastic skin of IL10/, IL-10TG, and WT mice.
(I) Quantitative RT-PCR measurement of mRNA levels of cytotoxic molecules in skin of WT and IL10/ mice. Error bars represent standard error of the mean.
(J–L). Infiltration of CD8b+ (J) and CD8a+ (K) T cells and IFNg expression (L) in the carcinogen-treated skin of IL10/, IL-10TG, and WT mice. Horizontal bars
represent mean and each data point (dots) represents one mouse in (A), (C–F), and (J–L). *p < 0.05, **p < 0.01, ***p < 0.001.
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IL-10 Induces IFNg-Mediated Tumor Immunitypresentation molecules, but even appears to promote their
induction.
MHC Molecules and Cytotoxic Mediators Are Increased
by IL-10 in the Tumor but Not in Secondary Lymphoid
Organs
The above findings raised the question whether stimulation of
peripheral tumor immune surveillance with IL-10 would inhibit
the growth of already established tumors. Recombinant human
IL-10 has been used previously to induce rejection of trans-
planted fibrosarcomas in mice (Berman et al., 1996; Fujii et al.,
2001). Recombinant human and mouse IL-10 have short in vivo
half lives and human IL-10 is potently immunogenic in murine
models (data not shown). Therefore we utilized a pegylated
form of murine IL-10 (PEG-IL-10) with an increased serum half
life for most of the animal experiments described in this study.
Cancer cell lines used in transplanted tumor models might
have acquired mutations during in vitro passage, possibly
making their antigenic profile an easier target for cancer immune
therapy compared with endogenous tumors. In addition, rela-
tively slow developing endogenous tumors might pose a signifi-
cantly different challenge to the immune system than rapidly
growing transplanted tumors. Moreover, large tumor masses
are frequently resistant to intervention with chemotherapies but
are even more resistant to immune therapies. Therefore we
tested the antitumor effects of PEG-IL-10 in large tumors devel-
oping in Her2 transgenic mice (FVBMMTV-rtHer2), an endogenous
mouse model for breast cancer, and found that PEG-IL-10 con-
trolled average tumor growth and induced rejection of several
well-established large tumors (Figures 2A–2C).
It has been shown that IL-10 reduces the expression of antigen
presenting molecules in vitro and suppresses the expression of
inflammatory cytokines (Moore et al., 2001). IL-10-deficient
animals develop autoinflammatory colitis (Ku¨hn et al., 1993). In
addition, overexpression of IL-10 peripherally in the brain, but
not systemically, reduces inflammatory responses in a mouse
model of multiple sclerosis driven by inflammatory Th17 CD4+
T cells (Cua et al., 1999). In contrast to IL-10s reported inhibition
of angiogenesis, inflammation, and antigen presentation, PEG-
IL-10 treatment of Her2 transgenic mice carrying mammary
carcinomas did not reduce intratumoral angiogenesis or infiltra-
tion of inflammatorymacrophages (Figures 2D and 2E). Themost
striking IL-10-induced change in the tumor microenvironmentFigure 2. IL-10-Mediated Control of Endogenous Her2 Transgenic T
Expression in the Tumor
(A–C) PEG-IL10 treatment effect on the growth of endogenous mammary canc
(0.5 mg/kg) nR 8/group in three experiments, nR 3mice/group analyzed. Averag
(B) and PEG-IL-10-treated (C) mice.
(D–G) Horizontal bars represent the mean and each data point (dots) represents
random from each group with 20 images quantified per tumor. Data (D–I) is rep
(D) Angiogenesis as measured by CD31+ cells. (E) Infiltration of CD11b+ inflamm
(F–I) CD8+ T cells infiltration in response to IL-10 treatment. Analysis of (F–I) wa
20 images quantified per tumor. Quantitation of CD8a and CD8b IHC results (F a
(J–M) Data are representative of three experiments with seven to ten mice/group
mRNA levels (L) and MHCII mRNA levels (M) in the tumor and spleen.
(N–P) Tissue from three to four mice/group analyzed from two independent experim
mean and each data point (dots) represents analysis of one mouse. Panels repres
tumor; quantitation of IHC results (P). IHC or mRNA analysis was performed 3 w
represents standard error of the mean for all panels. See also Figure S1.
Canwas a significant increase of CD8a/b+ T cell infiltration (Figures
2F–2I). Contrary to the known anti-inflammatory role of IL-10
however, IL-10 treatment elicited dramatically increased expres-
sion of the Th1 cytokine IFNg predominantly in the tumor, and to
a lesser extent in the spleen (Figures 2J and 2K). In addition,
PEG-IL-10 significantly induced the intratumoral expression of
MHC-I and MHC-II molecules, both at the RNA and protein level
(Figures 2L–2P). Interestingly, most of the areas in IL-10-treated
tumors showed a significantly higher expression of MHCII than
all areas in a control tumor (Figure S1A available online). Despite
systemic exposure to IL-10, antigen presentation in the spleen
was only moderately regulated (Figures 2L and 2M). To test the
importance of CD8+ T cell-mediated immune surveillance for
IL-10-induced tumor control, we depleted CD8+ T cells with anti-
bodies. Depletion of CD8+ T cells abrogated the antitumor
activity of IL-10 (Figure S1B). Importantly, the significant stimula-
tion of peripheral antitumor immunity by PEG-IL-10 extended to
a wide variety of large transplanted tumor types and mouse
strains even when the primary tumors were very well established
(Figures S1C–S1F).
Activation of CD8+ T Cells in the Tumor but Not
in Secondary Lymphoid Organs Is Essential to
IL-10-Mediated Tumor Immune Surveillance
IL-10 has been suggested to boost immune effectors (Fujii et al.,
2001) but derail immunization and inhibit memory responses to
tumor antigens (Fujii et al., 2001; Vicari et al., 2002). The obser-
vation of peripheral effector T cell activation with minimal sys-
temic immune stimulation could explain the inhibition of long
term T cell memory by IL-10 reported previously (Brooks et al.,
2006). To test for protective tumor-specific CD8+ responses
and antitumor immune memory responses we employed a skin
squamous carcinoma model (PDV6) syngeneic to C57BL/6
harboring the same Ha-Ras mutation as the chemically-induced
tumor model. These tumors grow orthotopically in the skin and
metastasize via the lymphnodes to the lung and the bone, similar
to human skin or breast carcinomas. Compared to WT mice, the
progression of this carcinoma was significantly faster in IL-10/
mice leading to 50% of the mice succumbing to the tumor and
metastasis within 3 months (Figure 3A). When treated with
PEG-IL-10, mice carrying PDV6 carcinomas rejected their
tumors even if the treatment was initiated at late tumor stages
and large tumor masses (Figure 3B). Mice cured by IL-10umors Is Accompanied by Infiltration of CD8+ T Cells and MHC
er in FVBMMTV-rtHer2 mice. Horizontal bar in (A) indicates treatment duration
e tumor burden (A) and beginning and ending volumes of each tumor of control
analysis of one mouse. (D) and (E) were performed on three mice selected at
resentative of two independent experiments each quantified in this manner.
atory macrophages.
s performed on three to five mice selected at random from each group with
nd G) and examples for CD8a in control (H) and PEG-IL-10 (I) tumor tissue.
. Data represent IFNgmRNA levels in tumor (J) and spleen (K). (L and M) MHCI
ents with 20 fields per tumor quantified and in (P) horizontal bars represent the
ent immunohistochemistry staining of MHCII in a control (N) or IL-10 treated (O)
eeks after treatment initiation. *p < 0.05, **p < 0.01, ***p < 0.001. Error bar(s)
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IL-10 Induces IFNg-Mediated Tumor Immunitytreatment were resistant to reimplantation of the same tumor,
tested up to 8 months after tumor rejection. This protection
was comparable to or better than tumor vaccination with
freeze-thawed tumor cells (Figure 3C). Clearance of primary
tumors by IL-10 treatment was therefore able to stimulate
a potent protective long-term immune memory against rechal-
lenge with the same tumor. Similarly, treatment only during the
first 10 days after tumor inoculation does not suppress the
host immune systems antitumor response (Figure 3D and data
not shown). These data indicate that IL-10 induces an effective
immunological memory toward tumor antigens and does not
derail immunological memory. Similar to overexpression of
IL-10 in the chemically-induced tumors, IL-10 treatment of
orthotopic squamous carcinomas resulted in a significant in-
crease of CD8+ T cells (CD8a/b+) detectable in and extractable
from tumor tissue (Figure 3E).
Tumor-specific T cells isolated from tumors or the blood of
human cancer patients can frequently be restimulated in vitro
to proliferate or to produce IFNg, however, it is their activity
inside human tumors that is thought to confer a prognostic
advantage (Galon et al., 2006; Naito et al., 1998). We therefore
examined the mRNA expression profile and the release of gran-
zymes and IFNg from tumor-infiltrating CD8+ T cells without
further in vitro stimulation. The expression of cytotoxic markers
such as granzymes and perforin as well as IFNg was strongly
enhanced in CD8+ T cells extracted from tumors of PEG-IL-10
treated mice, but only limited changes were observed in sec-
ondary lymphoid organs such as the spleen and lymphnodes
(Figures 3F, S2A, and data not shown). PEG-IL-10 treatment
induced a 3- to 4-fold increase in the spontaneous secretion
of Granzyme B and IFNg by tumor-derived CD8+ T cells (Figures
3G and 3H).
As PEG-IL-10-induced granzymes expression in the tumor
and tumor-infiltrating CD8+ T cells, we sought to identify the
cellular requirements for its tumor inhibition. PEG-IL-10 failed
to inhibit growth of syngenic tumors grown in mice deficient for
the adaptive immune response (RAG/ and nude mice; Fig-
ure S2B and data not shown). Mice deficient in B cells however
responded similarly to WT mice indicating a limited involvement
of B cells (data not shown). Antibody-mediated depletion of
CD8+ T cells but not of CD4+ T cells completely abrogated anti-
tumor function of IL-10 indicating that stimulation of CD8+ T cell
function is absolutely required for IL-10-mediated tumor rejec-
tion (Figure 3I). CD8+ T cells were also required in other tumorFigure 3. IncreasedCD8+ T Cell Activity in the Tumor but Not in Seconda
(A and B) Data in (A) reflect two independent experiments with n = 5–10 mice/g
IL-10/ and WT C57BL/6 mice after PDV6 squamous tumor implantation. (B) P
(C) Data represents two experiments with n = 10 mice/group, one reimplantation
inhibition of primary tumor growth implanted up to 8 months after rejection of th
(D) Two independent experiments (n = 10 mice/group). Data represent analysis
tumor implantation (treatment period indicated by horizontal bar below graph).
(E) Representative three experiments (n = 10 mice/group). Each tumor was section
per section under blinded conditions. Data represent the quantification (blinded)
(F) Three independent experiments with n = 10 mice/group of the mRNA analysi
(G and H) Six independent experiments. ELISPOT analysis of purified tumor-infilt
(G) and Granzyme B (H).
(I) Reflects data representative of six independent experiments in different tumor
CD4 or CD8 to deplete specific cell populations or isotype control to analyze ce
represent standard error of the mean for all panels. *p < 0.05, ***p < 0.001; 10 m
Canmodels like the endogenous breast cancers in HER2 transgenic
animals (Figure S1B). Depletion of NK cells did not have a signif-
icant effect on IL-10-mediated rejection of PDV6 tumors (Fig-
ure S2C). Taken together, these data indicated that the immune
stimulation by IL-10 primarily requires the activation of peripheral
T cells and CD8+ cytotoxic T cells in particular. Importantly, the
induction of MHC-I/II by IL-10 was reduced upon antibody-
mediated T cell depletion, in particular when CD8+ T cells were
depleted (Figures S2D and S2E). These data suggested that
IL-10-induced activation of CD8+ T cells in the tumor microenvi-
ronment may lead to T cell-mediated upregulation of antigen
presenting molecules.
IL-10 Induces Antigen-Specific CD8+ T Cell Responses
in Tumor-Bearing Mice and Elevates IFNg in CD8+
T Cells
We next asked if IL-10 alters the frequency of antigen-specific
responses to the tumor. CD8+ T cells were isolated from the
blood or the tumor and in vitro stimulated with soluble anti-
CD3 antibodies, the cognate tumor cells (PDV6) or an irrelevant
tumor cell line (Figures 4A–4C). Within 4 days, IL-10 treatment
increased the number of cells responding to anti-CD3 stimula-
tion with IFNg secretion in cells isolated from the tumor, indi-
cating broad Tc1 polarized activation of CD8+ T cells in IL-10
treated mice. However the frequency of tumor cell-specific
responses were low, both in control and IL-10 treated tumors.
Interestingly, after allowing polyclonal T cell expansion by treat-
ing with IL-10 for 2 weeks, equal numbers of cells responded to
anti-CD3 stimulation or to stimulation with the cognate tumor
cells (PDV6) but not to irrelevant tumor cells, indicating a high
degree of antigen specificity within the IL-10-induced CD8+
T cell response (Figure 4B). After 2 weeks in vivo IL-10 exposure,
both tumor-derived and blood-derived CD8+ T cells secreted
IFNg when restimulated with their cognate tumor in vitro (Fig-
ure 4C) indicating a systemic expansion of the tumor-specific
CD8+ T cells repertoire in the host.
Direct analysis of whole tissue mRNA detected greater IFNg
induction in the tumor, compared to other tissues or the blood
of IL-10 treated animals. We therefore isolated CD8+ T cells
from large tumors or the blood of mice treated with IL-10 and
stained for intracellular IFNg directly without in vitro restimula-
tion. Interestingly, only T cells isolated from the tumors treated
with PEG-IL-10 expressed intracellular IFNgwithout the require-
ment for further in vitro restimulation whereas T cells isolatedry Lymphoid Organs Is Necessary for IL-10-Mediated Tumor Control
roup, (B) four experiments with n = 10 mice/group. (A) Represents survival of
EG-IL-10 therapeutic effect on growth of established PDV6 tumors.
at 5 months and one at 8 months post complete tumor rejection. Panel reflects
e primary tumor.
of tumor growth after treatment with PEG-IL-10 for 10 days concomitant with
ed twice and two independent investigators acquired and analyzed 25 images
of intratumoral CD8b T cell identified by IHC normalized on all nucleated cells.
s of tumor-infiltrating CD8+ T cells for cytotoxic effector molecules.
rating CD8+ T cells (TIL) reporting numbers of cells (5,000/well) secreting IFNg
models with n = 5–10 mice/group. Mice were treated with antibodies against
llular requirement for PEG-IL-10-induced effect on tumor growth. Error bar(s)
ice/group, treated with 0.5–0.1 mg/kg PEG-IL-10. See also Figure S2.
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Figure 4. IL-10 Increases Antigen-Specific T Cell Responses, Directly Induces IFNg in Tumor-Infiltrating IL10R-Positive CD8+ T Cells but
Does Not Require IFNg for Induction of Cytotoxicity Effector Molecules
(A–C) Panels are representative of three independent experiments in PDV6 and two independent experiments in CT26 (n = 5–10 mice/group). ELISPOT data for
the analysis of antigen-specific CD8+ T cells isolated from tumors (TILs) or blood were stimulated with anti-CD3, cognate tumor cells (PDV6), or MHC matched
nonprimary control tumor cells (EL-4); IFNg positive ELISPOTS (1,000 cells/well with E/T of TILs to tumor cells at 10:1) were normalized to untreated
nonstimulated controls. TILs were analyzed after 4 days (A), 17 days (B), and blood CD8+ T cells analyzed at 17 days (C) of dosing.
(D) Quantitation of intracellular IFNg by FACS of TILs, reflecting four independent experiments.
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T cells isolated from secondary lymphoid organs such as the
spleen or the tumor draining lymph node also required in vitro
restimulation to express IFNg (data not shown).
IL-10RA Is Highly Expressed on Tumor-Infiltrating
CD8+ T Cells
These data raised the question why tumor-infiltrating CD8+
T cells were uniquely able to respond to IL-10 with IFNg produc-
tion. To test the hypothesis that CD8+ T cells in different locations
differentially express the IL-10R, we stained various cell types for
the expression of the IL-10R from different tissues. IL10R was
expressed significantly higher on CD8+ T cells isolated from
tumors but barely detectable on cells derived from blood or sec-
ondary lymphoid organs (Figures 4E, S3A, and S3B). This may
provide a molecular explanation for the unique activation of
peripheral, tumor-infiltrating CD8+ T cells by IL-10.
IL-10Directly ElevatesCytotoxicity and IFNgExpression
in CD8+ T Cells
During acute virus infection autocrine IL-10 has been found to
limit the activation and the expressions of signature cytokines
such as IFNg in Th1 CD4+ T cells (O’Garra and Vieira, 2007).
However, IL-10 has previously been shown to enhance IL-2-
induced cytotoxic activity of CD8+ T cells (Chen and Zlotnik,
1991; Groux et al., 1998). The absolute requirement for IL-2
and the molecular targets of the increased cytotoxic activity
remains undefined. Moreover, under physiological conditions
IL-2 is not thought to be elevated in tumors. To assess IL-10
capacity to stimulate CD8+ T cell cytotoxic function, spleen-
derived CD8+ T cells were activated in vitro, rested, and then
exposed to increasing concentrations of IL-10 in vitro in the
absence of exogenous IL-2. IL-10 directly elevated the expres-
sion of cytotoxic enzymes and the expression of the Th1 cyto-
kine IFNg in CD8+ T cells, once again contradicting expectations
(Figure 4F). Using T cell receptor transgenic CD8+ T cells we
found that IL-10 alone was also sufficient to enhance their
cytotoxic activity toward target cells pulsed with the cognate
peptide antigen (Figure 4G). The levels of IL-10 required to
activate CD8+ T cells in vitro were comparable to serum con-
centrations achieved in mice treated with therapeutic doses of
PEG-IL-10 (data not shown). These data are seemingly in con-
trast to previously published results that analyzed CD8+ T cell
responses either in coculture systems with dendritic cells
(Kang and Allen, 2005) or with Listeria-infected target cells. We
hypothesize that under such conditions, IL-10 may antagonize
and compete with dendritic cell-derived IL-12. IL-12 induces
IFNg and Th1 polarization of T cells. Expression of IL-12, how-
ever, is very limited in the tumor microenvironment (Langowski
et al., 2006). Moreover, preliminary data suggest IL-10 induces
tumor rejections in both WT and IL-12 deficient animals (data
not shown). These findings suggest that IL-10 may represent
an alternative pathway to induce IFNg in tumor-infiltrating
CD8+ T cells, independent of IL-12 or IL-2.(F) Five independent experiments assessing effect of IL-10 on expression of cyto
(G) Analysis of IL-10 effect on OT-1 CD8+ T cells cytotoxicity in vitro, representa
(H) Investigation from four independent experiments of IL-10 effect on granzymes
bar(s) represents standard error of the mean for all panels. *p < 0.05, **p < 0.01,
CanIL-10 Induces Cytotoxic Enzymes in CD8+ T Cells
Independently of IFNg
IFNg is essential for CD8+ T cell-mediated immune surveillance
(Dunn et al., 2006). To test if upregulation of IFNg mediates the
cytotoxicity induced by IL-10, we investigated the modulation
of cytotoxic molecules in IFNg/ T cells. IFNg/ CD8+ T cells
were isolated, activated in vitro, rested, and exposed to various
concentrations of IL-10. Unexpectedly, IL-10 induced the upre-
gulation of mRNA for granzymes and perforin in IFNg/ CD8+
T cells equally to WT CD8+ T cells (Figures 4F and 4H). We
also asked if exogenous IFNg would enhance the effect of
IL-10 on the expression of those cytotoxic mediators in IFNg/
CD8+ T cells. Under these conditions, IFNg neither directly stim-
ulated nor enhanced IL-10s induction of granzymes or perforin
(Figure S3C). These experiments indicate that although IL-10
induces IFNg in CD8+ T cells, the stimulation of cytotoxic mole-
cules in CD8+ T cells in vitro by IL-10 is independent of IFNg.
They also suggest that IL-10 is a key regulatory cytokine to
induce the expression of cytotoxic enzymes.
IL-10-Mediated Tumor Rejection Depends on IFNg, but
Infiltration of CD8+ T Cells and the Intratumoral
Induction of Cytotoxic Enzymes Do Not
Wenext tested the requirement for IFNg in IL-10-mediated tumor
immune rejection using the orthotopic PDV6 model. IL-10
controls tumor growth (Figure 5A) and significantly increased
intratumoral CD8+ T cell infiltration in this tumor, similar to the
DMBA-induced skin tumors (Figure 3E). However, in IFNg/
mice, even though IL-10 treatment induced a similar increase
of intratumoral CD8+ T cells, it failed to induce tumor rejection
(Figure 5B). Consistent with in vitro findings, the induction of
cytotoxic molecules were similarly upregulated in the tumors
and in CD8+ T cells isolated from IL-10 treated WT and IFNg/
mice (Figures 5C–5E). This suggests that both IL-10-mediated
intratumoral T cell infiltration and induced expression of cytotox-
icity in CD8+ T cell in vivo is largely independent of IFNg. In most
experimental antitumor immune therapy approaches, the acti-
vation of tumor-infiltrating cytotoxic T cells correlates with the
elimination of tumor cells. Our data suggest that CD8+ T cell acti-
vation by IL-10 in the absence of IFNg uncouples this correlation,
with IL-10 driving efficient infiltration and activation of the CD8+
T cells. However, elimination of tumor cells by these granzyme-
and perforin-expressing CD8+ T cells still required IFNg (Figures
5A and 5B and data not shown).
IL-10 Induces Upregulation of MHC Molecules through
Induction of T Cell-Derived IFNg
In vitro IL-10 reduces the expression of MHC molecules in
antigen presenting cells (Moore et al., 2001). IFNg has been
shown to induce MHC expression in antigen presenting cells
and in human, mouse tumor cells, or tumor stroma (Seliger
et al., 2002, 2001; Zhang et al., 2008). Our data show that IL-10
induces IFNg in CD8+ T cells. We hypothesized that host-derived
IFNg might therefore be essential to mediate IL-10-inducedtoxic effector molecules and IFNg in CD8+ T cells in vitro.
tive data from three independent experiments.
and perforin mRNA expression in CD8+ T cells from IFNg/mice in vitro. Error
***p < 0.001. See also Figure S3.
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Figure 5. Uncoupling of CD8+ T Cell Infiltration and Cytotoxic Activity from MHCI and MHC-II Induction and Tumor Rejection
(A and B) Data represents four experiments (n = 7–10 mice/group). PEG-IL-10 antitumor function in WT (A) and IFNg/ (B) mice.
(C) Analysis of PEG-IL-10 effect on intratumoral CD8+ T cell infiltration in both WT and IFNg/mice (IHC CD8a+ cell quantitation, bars represent mean for all
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Therapeutic administration of PEG-IL-10 induced a potent upre-
gulation of mRNAs for MHC-I and II molecules in WT tumors in
WT hosts (Figures S4A–S4D), but the same WT tumors failed to
express MHC molecules in IFNg/ hosts irrespective of IL-10
treatment (Figure 5F). Similarly, IL-10 induced MHC I and II
protein expression was detected only in tumors in IFNg compe-
tent animals (Figures 5G and S4E–S4H). Contrary to our current
understanding of the immune regulatory function of IL-10, these
data suggest not only that IL-10 induces the Th1 cytokine IFNg
in intratumoral CD8+ T cells but also that the IFNg-mediated in-
duction of intratumoral antigen presentation machinery is essen-
tial for the antitumor function of IL-10.
The majority of human tumor cells upregulate antigen presen-
tation upon IFNg treatment in vitro, but tumor cells can escape
immune recognition by altering their MHC and antigen process-
ing machinery (Seliger et al., 2002). We therefore tested if IL-10
could induce rejection of tumors with reduced IFNg responsive-
ness. We screened several syngeneic tumor cell lines for IFNg-
induced upregulation of antigen presentation and expression
of MHCI in particular. The lung carcinoma cell line LL/2 is largely
resistant to upregulation of cell surface MHCI when exposed to
IFNg in vitro (Figure 5H). We therefore tested if IL-10 treatment
would still suppress growth of LL/2 tumors. Therapeutic admin-
istration of IL-10 induced the mRNA expression of cytotoxic
enzymes and IFNg in LL/2 tumors (Figure 5I and data not shown).
As predicted by the proposed model, IL-10 treatment or more
specifically IL-10-induced-IFNg failed, however, to upregulate
intratumoral expression of MHCmolecules and correspondingly
failed to suppress tumor growth (Figures 5I and 5J).
Human Inflammatory Diseases but Not Cancer Exhibit
Elevated IL-10 Expression
IL-10 is thought to be primarily antiinflammatory and im-
mune suppressive. Consequently, IL-10 is suspected to in-
duce tumor-associated immunosuppression (Niederkorn, 2008).
Chronic inflammatory diseases like ulcerative colitis (UC) are
statistically significantly associated with an increased risk of
cancer incidence. Inflammatory cytokines like IL-23 are ex-
pressed highly in inflammatory lesions of such patients and may
also contribute to tumor-promoting inflammation (Langowski
et al., 2006 and data not shown). We therefore evaluatedwhether
IL-10expressionmaybe lower in inflammatoryboweldiseaseand
higher in colon tumors. On the contrary, IL-10 was significantly
elevated in ulcerative colitis and Crohn’s disease (Figure 6A),
very similar to proinflammatory cytokines (data not shown).More-(D) Quantitation of mRNA for cytotoxic effector molecules from tumors of PEG
experiments (n = 3–10 mice/group), one PEG-IL10 and one minicircle.
(E) Comparison of CD8+ TILs secretion of Granzyme B (ELISPOT) upon PEG-IL-1
TILs of ten mice per treatment pooled and analyzed.
(F and G) PEG-IL-10 regulation of MHC molecules expression in tumors grown
quantitation of intratumoral MHC I, panel data representative of two experimen
analyzed.
(H) FACS analysis of MHCI regulation after in vitro stimulation of tumor cells w
experiments.
(I) Experimental data from three experiments, n = 3–10 mice/group where data is
(J) Effect IL-10 treatment exerts on LL/2 tumor growth in vivo, where data is repr
IL-10 derived fromminicircle. Error bar(s) represents standard error of the mean fo
of increased serum IL-10, average tumor sizes plotted. See also Figure S4.
Canover, IL-10 was expressed lower in colonic polyps compared to
normal tissues and there was no difference of IL-10 mRNA
when colorectal cancer tissue was compared to normal adjacent
tissue (Figure 6B). Similarly, IL-10mRNAexpressionwithin breast
cancer tissue is equal to normal, noninflamed adjacent tissue
controls (Figure 6C) and the IL-10 concentration in the serum of
breast cancer patients and normal volunteers was similar (Fig-
ure 6D). Thus, contrary to the prevailing expectations, IL-10
mRNA expression was not increased in any human carcinoma
type investigated, butwas significantly upregulated under inflam-
matory conditions.
IL-10 Directly Induces Cytotoxicity of Human CD8+ T
Cells and Its Expression Correlates with the Expression
of Cytotoxic Enzymes
We next confirmed that IL-10 regulates cytotoxic enzymes and
the Th1 cytokine IFNg also in human CD8+ T cells (Figure 6E).
These data suggest that IL-10 regulation of cytotoxic activity
and IFNg expression is similar in CD8+ T cells from mice and
man. The direct activation of cytotoxicity led us to investigate
the nature of such CD8+ T cell activation. mRNA of granzymes
and perforin was strongly induced within a few hours of IL-10
stimulation (Figures S5A–S5C) suggesting a direct transcrip-
tional activation by IL-10-induced signaling. IL-10 is known to
induce phosphorylation and activation of Stat3. Indeed, addition
of a Stat3 inhibitor to CD8+ T cell could partially abrogate IL-10-
mediated induction of cytotoxic enzymes (Figure 6F), supporting
involvement of Stat3 in the induction of cytotoxic enzymes by
IL-10.
Expression of IL-10 in human tissue and tumors might cor-
relate with the expression of cytotoxic enzymes if IL-10 directly
induces the expression of cytotoxic enzymes. Indeed, IL-10
and Granzyme B expression were highly correlated in melanoma
samples (Figures 6G and 6I). IL-12 (IL12p35), stimulates Gran-
zyme B expression in CD8+ T cells and its expression also cor-
related with Granzyme B expression in melanoma tissues
(Figures 6H and 6I).
Given the antitumor function inmouse carcinomas of IL-10, we
further analyzed if the expression of IL-10 would also correlate
with the expression of cytotoxic enzymes, the expression of
antigen presenting molecule, and the expression of IFNg in
human colorectal cancers (CRC) and normal adjacent tissue. In
support of an induction of immune surveillance molecules by
IL-10, expression of all three classes of molecules mediating
cytotoxicity and immune recognition correlated very strongly
with intratumoral IL-10 expression (Figures 6J–6L, S5D, and-IL-10 or control treated WT or IFNg/ mice. Analysis representative of two
0 treatment in WT and IFNg/ mice. Data representative of two experiments,
in WT and IFNg/ mice as determined by mRNA quantitation (F). (G) IHC
ts, three to five tumors taken per treatment group, 20–25 images per tumor
ith IFNg, LL/2 compared with PDV6 tumor cells, data representative of three
the analysis of LL/2 tumor mRNA from IL-10 versus control treated mice.
esentative of three independent experiments, once with PEG-IL-10, twice with
r all panels. *p < 0.05, **p < 0.01, ***p < 0.001, horizontal bars indicate duration
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Figure 6. IL-10 Expression in Chronic Inflammation but Not in Tumor-Associated Inflammation -IL-10 Directly Correlates with Granzyme
Expression in Human Tumors
(A–D) Inflammatory and cancer associated IL-10 expression. Association of hIL-10 mRNA expression with inflammation in human ulcerative colitis and Crohn’s
disease (A), colon cancer (B), human breast cancer (C), and IL-10 protein in serum of breast cancer patients (D).
(E) IL-10 regulation of cytotoxic enzymes mRNA in human CD8+ T cells (data representative of 15 independent experiments) in vitro.
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expression of MHC I and MHC II correlated with IL-10, but not
with IL-12 in the tested human CRC (Figures S5F–S5H). These
data may suggest that IL-10 is more important for the regulation
of CD8+ activity and antigen presentation in human tumors than
previously anticipated.
DISCUSSION
The data presented here challenge our current perception of how
the immune system is regulated during tumor immune surveil-
lance and the role of IL-10 therein. First, IL-10 is required for effi-
cient immune surveillance against the incidence and progression
of endogenously arising skin tumors. Second, IL-10 induces the
expression of MHCI and IFNg in tumors, two key molecules for
immune surveillance against tumors. Third, our data suggest
IL-10 induces the production of cytotoxic enzymes and IFNg
primarily in tumor-infiltrating CD8+ T cells by virtue of their high
IL-10R expression.
The specific delivery of cytotoxic molecules to antigen ex-
pressing tumor cells by IL-10 requires the IFNg-mediated upre-
gulation of MHC molecules on the target cell. In human cancer
patients, both MHC expression and CD8+ T cell activity in the
tumor are very low but the presence of both have been corre-
lated to improved survival of cancer patients (Galon et al.,
2006). Interestingly, IL-10 expression in colorectal cancers cor-
related not only with the expression of granzymes, but also
with the expression of IFNg and antigen presenting molecules
such as HLA-DR. Most experimental tumor immune therapies
aim to rapidly increase the number of tumor-specific CD8+
T cells in the patient or the experimental animal. Unfortunately,
the efficacy of such experimental immunological interventions
is even in experimental tumor systems frequently limited to
the early phases of tumor growth and to particularly immune-
sensitive tumor types. Such rapid CD8+ T cell expansions require
involvement of secondary lymphoid organs as the site of antigen
presentation and a strong stimulation of CD4+ T helper cells.
Although IL-10 has been shown to interfere with the activity
and polarization Th1 and IFNg production of CD4+ T cells in
response to bacterial products (O’Garra and Vieira, 2007), we
find that IL-10 directly activates and expands the antigen-
specific, IFNg producing CD8+ effector T cell pool in the tumor,
leading to enhanced expression of intratumoral antigen pre-
senting molecules. The direct activation of CD8+ T cells appears
to circumvent the absolute requirement for CD4+ T cell help.
Aside from indirect effects on antigen presentation, specific
delivery of IFNg to the tumor cells may also increase the sensi-
tivity to apoptosis in tumor cells.
IL-10 is thought of as a broadly immune inhibitory cytokine, but
the immune suppressive effects of IL-10 are most prominently
uncovered in experimental and physiologic settings dependent
on TNFa, such as Toll like receptor (TLR)-mediated immuniza-(F) Effect of blockade of STAT3 phosphorylation on regulation of perforin expres
error of the mean.
(G–I) Correlation plot between the mRNA expression of IL-10 with Granzyme B
correlation with significance (I).
(J–L) Correlation between IL-10 and MHCI (HLA-A) (J) or Granzyme B (K) mRNA
significance for IL-10 and MHCII (HLA-DR), MHCI (HLA-A), Granzyme B, and IFN
Cantions with bacterial cell wall products and bacterial oligonucleo-
tides or T cell costimulation such as with anti-CD40. In stark
contrast, treatmentwithPEG-IL-10exerts a verypotent activation
of the tumor-infiltrating effector T cell pool despite suppression of
systemic TNFa and very limited systemic T cell responses. The
therapeutic levelsof IL-10used inour studiesaresimilar toendog-
enous high levels of IL-10 experienced under physiological stress
conditions such as sepsis or pneumonia (Deng et al., 2006; Sawa
et al., 1997; Steinhauser et al., 1999) (data not shown). TNFa is
rate limiting for chemically-induced skin carcinomas and TNFa
neutralizing antibodies are in clinical trials for treating several
tumor types (Szlosareket al., 2006). It is possible that suppression
of TNFa production contributes to the antitumor effect of IL-10 by
limiting tumor-promoting innate inflammation.
Chronic inflammation is associated with increased incidence
of cancer. Inflammatory cytokines like IL-1b and TNFa, in turn,
are associatedwith decreased survival of human cancer patients
(MummandOft, 2008). Many of these cytokines are expressed in
human tumor tissue and in chronic inflammatory lesions at simi-
larly high levels. Surprisingly, we found that IL-10 is not elevated
in human tumor tissue, despite the presence of inflammatory
cells and the prominent expression of other inflammatory cyto-
kines such as IL-23 (Langowski et al., 2006). Moreover, ex-
pression of IL-10 correlated with the expression of cytotoxic
mediators such as Granzyme B suggesting that endogenous
IL-10 regulates cytotoxic activity of the immune response within
human tumors similar to the mouse models analyzed in this
study. These data also support the concept that tumor-associ-
ated inflammation may share many characteristics with chronic
inflammatory lesions such as the expression of proinflammatory
cytokines, but not the expression of IL-10 or cytotoxic enzymes.
Tumors, therefore, appear to thrive in an inflamed environment
poor in cytotoxic effector cells and low in IL-10.
In many experimental settings in vitro, IL-10 has been shown
to antagonize the expression and function of the Th1 cytokine
IFNg, with primary CD4+ T cell proliferation and Th1 polarized
T cell cultures being especially sensitive to IL-10 (Moore et al.,
2001). Overexpression of IL-10 in mice can inhibit experimental
autoimmune encephalitis (EAE), a disease mediated by proin-
flammatory IL-17 producing CD4+ T cells (Cua et al., 1999;
McKenzie et al., 2006). Acute systemic inflammatory responses
and rapid systemic expansions of CD8+ T cells in secondary
lymphoid organs are dependent on TNFa and IL-12 and
enhanced when IL-10 or the IL-10 receptor is inhibited during
acute infection models (Brooks et al., 2006). In contrast, thera-
peutically elevated levels of IL-10 specifically enhanced expres-
sion of IFNg and granzymes peripherally in tumor-infiltrating
CD8+ T cells experiencing antigen. IL-10 stimulation of expres-
sion and secretion of IFNg by CD8+ T cells in vivo and in the
tumor appears to be direct. Moreover, based on studies in cyto-
kine knockout mice IL-10-mediated antitumor function appears
to be independent of TNFa and IL-12 (data not shown).sion by IL-10 (six independent experiments). Error bar(s) represents standard
(G) or IL-12p35 expression in human melanoma samples (H), and Spearman
expression in human colon cancer samples and Spearman correlation with
g (L). *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S5.
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secretion of cytotoxic molecules in CD8+ T cells in vitro and
in vivo. However, increased expression and release of cytotoxic
molecules from tumor-infiltrating T cells was not sufficient to
achieve significant antitumor function. Antitumor function and
tumor cell killing was dependent on IFNg secretion by IL-10 acti-
vated tumor-infiltrating CD8+ T cells. IFNg was required for the
upregulation of intratumoral MHC-I and MHC-II molecules but
not for cytotoxic enzymes or T cell infiltration. The expression
of MHC molecules in human cancers is typically very low and
thought to contribute to the immune evasion of human cancers
(Seliger et al., 2002). In vitro treatment of human and mouse
cancer cells with IFNg can restore expression of MHCmolecules
and the antigen processing pathways, indicating that these path-
ways are functional in tumor cells and are not genetically lost
(Seliger et al., 2002).
Effectiveness of immunotherapy is frequently limited by unin-
tended side effects, such as systemic autoimmunity, presum-
ably due to the reduction in signaling threshold of the T cell
receptor complex. PEG-IL-10-treated animals showed limited
systemic responses in primary and secondary lymphatic organs
with activation of T cells predominantly in the periphery and at
the tumor site (Figure 2 and data not shown). Infiltration of mono-
cytes and lymphocytes was found in many glandular organs
such as the parotid gland, the liver, and the pancreas in mice
treated with PEG-IL-10. The cellular components of this infiltrate
were similar in type and activation to infiltrates documented in
the tumors of such animals and lead in some organs to varying
degrees of immunopathology characterized by apoptosis of epi-
thelial cells. It remains unclear if the CD8+ T cells within these
parenchymal lesions are autoreactive or whether this represents
a not antigen-specific bystander effect. Althoughmice subjected
to a curative treatment schedule of PEG-IL-10 did not show
weight loss over 5%, this immune-mediated toxicity could lead
to dose limiting toxicities if observed in human cancer patients
treated with PEG-IL-10.
The lack of T cell infiltration, their diminished intratumoral
activity, and deficient MHC expression in tumors are prominent
mechanisms for tumor evasion in both mice and men. The
data presented here suggest that IL-10 can induce the minimal
immunological circuit required to overcome all three mecha-
nisms at once. By stimulating the activity of peripheral CD8+
T cells in the tumor, IL-10 delivers cytotoxic mediators and
IFNg to the tumor microenvironment without further activation
of central immune mechanisms. IL-10-induced elevation of the
Th1 cytokine IFNg locally in tumor-infiltrating CD8+ T cells may
facilitate chemokine cascades inducing further T cell infiltration
and increased antigen presentation primarily localized to the
tumor microenvironment. These data suggest that the use of
pegylated IL-10 as a monotherapy could elicit an immune
biology missing from most cytokine or vaccine therapies em-
ployed to date, and may therefore represent a beneficial treat-
ment for human cancer patients.EXPERIMENTAL PROCEDURES
Tumor Models
Chemical induction of skin tumors was performed as previously described
(Langowski et al., 2006). Three-month-old C57BL/6 or Balb/c mice were794 Cancer Cell 20, 781–796, December 13, 2011 ª2011 Elsevier Inctreated with 100 mg DMBA/mouse and then treated twice weekly with 30 mg
TPA for a duration of 5 months. For targeting IL-10 to antigen-presenting cells,
IL-10 transgenic mice expressing hIL-10 under the control of the MHCII
promoter were used (Groux et al., 1999).
Breast carcinomas in FVBMMTV-rtHer2 transgenic mice were monitored until
the tumor size reached between 100 and 2,000 mm3. Animals were allowed to
have up to two such large tumors. The mice were separated in two groups,
normalized for tumor size and total tumor burden per animal, and subjected
to PEG-IL-10 (0.5 mg/kg two times a day subcutaneously) or control
treatment.
In tumor transplantation studies, tumor cell lines were mixed with
50% growth-factor-reduced Matrigel (GIBCO) or resuspended in PBS and
injected subcutaneously or intradermally. Squamous carcinoma cells (PDV6
[Langowski et al., 2006]; DNAX) are derived from the DMBA transformed
keratinocyte cell line PDV (C57BL/6) and were orthotopically injected into
C57BL/6 mice (Langowski et al., 2006). CT-26, 4T1 (colon, breast cancer;
Balb/c) CM3 (melanoma; DBA) were received from ATCC and subcutaneously
implanted. Typically, tumors were left untreated for at least 2 weeks and until
they reached a size of 100–250mm3. For tumor rechallenge, micewere treated
until complete regression of the tumor, left untreated for up to 8 months, and
reinjected with the original tumor cell line. In the vaccine control arm, a freeze-
thaw preparation of the same tumor cell line was injected subcutaneously
three times several weeks before tumor rechallenge.
All animal experiments were performed under the guidance and approved
by the Institutional Animal Care and Use Committee of Schering-Plough Bio-
pharma, Palo Alto and in its Association for Assessment and Accreditation
of Laboratory Animal Care-approved facility.
Cytokine Treatment and Cell Depletion
PEG-IL-10 was injected at the indicated doses, typically 0.1 mg/kg or
0.5 mg/kg daily or twice daily for the times indicated by a black bar below
the x axis. Tumor growth was followed for an observation period of up to
3 months. The pegylated mouse IL-10 used in the studies has a serum T1/2
of 3.7 hr after subcutaneous injection. No anti-mIL-10 antibodies were
detected in mice after repeated dosing.
For cell ablation studies, 0.35 mg per mouse of anti-CD8 (53-6.7) 0.25 mg
per mouse anti-CD4 (GK1.5), or anti-NK1-1 (PK136) antibody at 0.3 mg
per mouse (ebioscience) was injected intraperitoneally once per week. For
depletion studies, animals were not dosed with PEG-IL-10 on the days they
received the antibodies to limit antiantibody responses. Antibodies were
dosed 3 days and 1 day prior to initiation of dosing with PEG-IL-10 and every
7 days thereafter.
Tumor-Infiltrating Immune Cell Analysis
Mouse tumor biopsies were harvested snap-frozen, fixed, and subjected to
immunohistochemistry (IHC) and counterstained with hematoxylin. Antibodies
used include MHC I, MHC II, CD3, CD31, CD8a, CD8b, CD4, CD11b, and
CD11c (Biolegend). Images of IHC for tumor-infiltrating cells were acquired
using Zeiss Mirax scanner and software. Randomly selected fields were quan-
tified either by manual counting or by using Zeiss Axiovision software (Carl
Zeiss, Jena, Germany) to measure the staining intensity or the number of posi-
tive events. Where intensity measurements were taken, the reduction in light
intensity per pixel in the respective color spectrum was recorded. The sum
of the light intensity reductions of all pixels in an identical region of interest
was calculated and plotted for all samples in one measurement group.
Some studies were counted blindly using random selected fields (number
set derived from http://www.random.org) and plotted against the treatment
groups after unblinding. For cell isolation, subcutaneous tumor masses were
dissected and digested with 2 mg/ml collagenase and 0.5 mg/ml DNase
(Sigma). Single-cell suspensions were created and live cells collected by
centrifugation over a Histopaque (Sigma) gradient. Similar isolations from
naive spleen were performed for comparison. Collected cells were positively
selected for CD8 by magnetic selection (Miltenyi Biotec).
Cytotoxicity Assay
Spleens and lymph nodes from OT1 mice were isolated and stimulated in
IMDM media supplemented with 5% FCS, containing 1 ug/ml SIINFEKL
peptide and 25 U/ml mIL-2 for 3 days in vitro. Activated CD8+ T cells were.
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cultured at 1 3 106 cells/ml in 48-well plates for 24 hr in the presence of
IL-10. Cells were counted, washed, andmixed with peptide pulsed target cells
(1 ug/ml 2 hr) or EG-7 target cells for 4 hr in U-96 well plates at an E/T of 10:1.
Cell supernatants were harvested and Cytotox 96 assays (Promega) were per-
formed following the manufacturers instructions.
ELISA and ELISPOT Analysis
ELISA assays from R&D Labs (Minneapolis, MN, USA) were performed
according to the manufacturer’s guidelines. Tumor-infiltrating (CD8+) T cells
were purified from tumor-bearing mice treated for 7 days with 0.1 mg/kg
PEG-IL-10 bid subcutaneously. Single cell suspensions of double purified
CD8+ T cells were plated at 10,000 and 25,000 cells/IFN-g or Granzyme B
ELISPOT well in triplicate, nonstimulated, or treated with PMA 20 ng/ml,
anti-CD3 soluble at 20 mg/ml, anti-CD3 beads 20 mg/ml, or Sepharose-Pro-A
beads. Isolated and purified TILs were exposed to these conditions for 24 hr
on ELISPOT membranes. ELISPOTs were developed following manufactures
instructions, counted, and quantified with Immunospot 3 (Cellular Technology
Limited, Cleveland). Antigen specificity was performed similar. Briefly, TILs
were isolated from individual tumors, five tumors in parallel, plated at 1,000,
2,000, and 5,000 cells/well in triplicate and exposed to media, 1 ug/ml anti-
CD3, or 10:1 E/T of cognate tumor or irrelevant tumor cells. Tumor cells
were exposed to 10 ng/ml IFNg for 24 hr prior to plating with TILS to ensure
MHC I expression that was verified by FACS analysis.
In Vitro CD8+ T Cell Assay
CD8+ T cells were isolated from tissue or peripheral blood using Miltenyi
Beads for enrichment. Cells were exposed 3 days to immobilized anti-CD3/
anti-CD28 at 10 and 2 ug/ml, respectively in AIM V, (human) or cRPMI con-
taining 1 mM b-mercaptoethanol and 10% FCS. Cells were washed into
AIM V and replated. IL-10 exposures ranged from 0.1 to 1000 ng/ml for
1 hr up to 3 days.
Human Tissue Samples
All human tissues were obtained under Institutional Review Board (IRB)-
approved protocols. Depending on the collection protocols established at
each site, tissues were acquired either under IRB-approved waiver of consent
(National Disease Research Interchange [NDRI] and Cooperative Human
Tissue Network [CHTN]) or by informed consent (Princess Alexandra Tumour
Tissue Bank [PAH], Zoion, Ardais, and Anatomical Gift Foundation [AGF]). All
samples have been de-identified or anonymized, so investigators have no
ability to identify the patients. Paired human tumor and normal adjacent
tissues were obtained from patients undergoing routine therapeutic surgery
from the following sources: Dr. David Gotley of the PAH in Woolloongabba
(Queensland Australia), Zoion Diagnostics (Hawthorne, NY, USA), and NDRI
(Philadelphia, PA, USA). Normal human tissue and inflammatory bowel dis-
ease tissue were obtained from patients undergoing routine surgery (NDRI,
Ardais Corporation [Lexington, MA, USA] and CHTN [Nashville, TN, USA]),
from short hour autopsy (%5 hr, Zoion Diagnostics), and from transplant
donors (AGF, Hanover, MD, USA). All surgical samples were frozen as quickly
as possible, typically within 1 hr of excision. The majority of samples were
accompanied by demographic information and pathology reports.
Gene Expression Analysis and Statistical Methods
All mRNA analysis was performed using quantitative RT-PCR. Briefly, total
RNA was isolated by standard methodologies and reverse transcribed. Ex-
pression analysis for marker-specific mRNAs was measured using real-time
quantitative PCR (ABI 5700) with SYBR Green PCR Mastermix (Applied Bio-
systems). Ubiquitin levels were measured in a separate reaction and used to
normalize the data by the D  DCt method, using the mean cycle threshold
(Ct) value for ubiquitin and the gene of interest for each sample. Statistical anal-
ysis was performed using GraphPad Prism software.
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